Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 3, 2004, Pages 791-799

  Plana, Montserrat ^a,i   Garcia, Felipe ^a   Oxenius, Annette ^b   Ortiz, Gabriel M ^c   Lopez, Anna ^a   Cruceta, Anna ^a   Mestre, Gabriel ^a   Fumero, Emilio ^a   Fagard, Catherine ^d   Sambeat, Maria Antonia ^e   Segura, Ferran ^f   Miró, José M ^a   Arnedo, Mireia ^a   Lopalcos, Lucia ^g   Pumarola, Tomas ^a   Hirschel, Bernard ^d   Phillips, Rodney E ^h   Nixon, Douglas F ^c   Gallart, Teresa ^a   Gatell, Jose M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL   (Switzerland)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f Neurology Section   (Spain)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

ⁱ HOSPITAL CLÍNIC   (Spain)

Author keywords

AIDS; Cytotoxic T lymphocytes; T lymphocytes; Th1 cells; Vaccination

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON;

ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STRUCTURED TREATMENT INTERRUPTION; TREATMENT PLANNING; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; GENES, MHC CLASS I; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 3042853112     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200407010-00005     Document Type: Article

References (28)

1. Rosenberg ES, Altfeld M, Poon S, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
2. Montefiori DC, Hill T, Vo H, et al. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1. J Virol. 2001;75:10200-10207.
3. Carcelain G, Tubiana R, Samri A, et al. Transient mobilization of human immunodefiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol. 2001;75:234-241.
4. Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F19-F27.
5. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in HIV infection. Arch Intern Med. 2003;163:1220-1226.
6. Garcia F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001;15:F29-F40.
7. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA. 2001;98:13288-13293.
8. Oxenius A, Price D, Gunthard HF, et al. Stimulation of HIV specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV-infection. Proc Natl Acad Sci U S A. 2002;99:13747-13752.
9. Matloubian M, Concepción RJ, Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 1994;12:8056-8063.
10. Hel Z, Nacsa J, Tryniszewska E, et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T-cell responses. J Immunol. 2002;169:4778-4787.
11. Lange C, Valdez H, Medvik K, et al. Earlier initiation of HAART better preserves functional immune competence even in persons who achieve "normal" CD4+ T-cell counts. Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona. Abstract LbOr09.
12. Parish MA, Tarwater PM, Lu M, et al. Prolonged treatment interruption after immunologic response to HAART.). Paper presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona. Abstract ThOrB1439
13. García F, Plana M, Ortiz GM, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003;17:43-51.
14. Schockmel G, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:179-183.
15. Plana M, García F, Gallart T, et al. Immunologic benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS. 2000;14:1921-1933.
16. Oxenius A, Price DA, Easterbook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-3387.
17. Haslett PA, Nixon DF, Shen Z, et al. Strong human immunodeficiency virus-specific CD4+ T-cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 2000;181:1264-1272.
18. Binley J, Schiller D, Ortiz GM, et al. The relationship between T-cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000;181:1249-1263.
19. Douek DC, Brenchley J, Betts M, et al. HIV preferentially infects HIV-specific CD4+ T-cells. Nature. 2002;417:95-98.
20. Blankson J, Gallant J, Quinn T, et al. Loss of HIV-1 specific immunity during treatment interruption in 2 chronically infected patients. JAMA. 2002;288:162-164.
21. Pitcher CJ, Quittner C, Peterson M, et al. HIV-1-specific CD4+ T-cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525.
22. Iyasere C, Tilton JC, Johnson AJ, et al. Diminished proliferation of human immunodeficiency virus-specific CD4+ T-cell is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J Virol. 2003;77:10900-10909.
23. Younes SA, Bader YD, Dumont AR, et al. HIV-1 viremia prevents the establishment of IL-2-producing HIV-specific memory CD4+ T-cells endowed with proliferative capacity. J Exp Med. 2003;198:1909-1922.
24. Oxenius A, McLean AR, Fischer M, et al. Human immunodeficiency virus-specific CD8+ T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol. 2002;76:10169-10176.
25. Yu XG, Addo MM, Rosenberg AS, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type I (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol. 2002;76:8690-8701.
26. Altfeld M, van Lunzen J, Fram N, et al. Expension of pre-existing, lymph node-localized CD8+ T-cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest. 2002;109:837-843.
27. Shedlock DJ, Shen H. Requirement for CD4 T-cell cell help in generating functional CD8 T-cell memory. Science. 2003;300:337-339.
28. Sun JC, Bevan MJ. Defective CD8 T-cell memory following acute infection without CD4 T-cell help. Science. 2003;300:339-342.